Dateline City:
London
Revenue potential significant; international interest following 2013 Ebola outbreak
London, UK (10 August, 2015) – Private companies are increasingly investing in the development of biological weapon countermeasures, according to a new report released today by IHS Inc. (NYSE: IHS), the leading global source of critical information and insight.
Download excerpts of the special report via IHSJanes360.com
Driven by high revenue potential and interest in the field following the 2013 Ebola outbreak, countermeasures against potential biological weapons are of increasing interest to pharmaceutical companies.
Language:
English
